RedHill Biopharma (RDHL) Income from Continuing Operations (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Income from Continuing Operations data on file, last reported at 80503000.0 in Q2 2023.

• Income from Continuing Operations for Q2 2023 came in at 80503000.0, up 1116.61% year-over-year; the trailing twelve-month figure through Jun 2023 was 22260000.0 (up 80.2% YoY), and the FY2025 annual result was 8080000.0, down 2344.44% from the prior year.
• Income from Continuing Operations grew to 80503000.0 in Q2 2023 per RDHL's latest filing, from 7919000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 80503000.0 in Q2 2023 and troughed at 145257000.0 in Q4 2021.
• A 5-year average of 248444.44 and a median of 11167500.0 in 2019 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2021 and 2023: Income from Continuing Operations plunged 1058.54% in 2021, then soared 1116.61% in 2023.
• A 5-year view of Income from Continuing Operations shows it stood at 11577000.0 in 2019, then surged by 30.9% to 15154000.0 in 2020, then sank by 1058.54% to 145257000.0 in 2021, then jumped by 46.15% to 78221000.0 in 2022, then soared by 202.92% to 80503000.0 in 2023.
• Business Quant data shows RDHL's Income from Continuing Operations at 80503000.0 in Q2 2023, 7919000.0 in Q1 2023, and 78221000.0 in Q4 2022.